Management of steroid resistant nephrotic syndrome

Indian Pediatrics

Volumn 46, Issue 1, 2009, Pages 35-47

  Bagga, Arvind ^a   Gulati, Ashima ^b   Gulati, Sanjeev ^b   Mehta, K P ^b   Vijayakumar, M ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NONE

Author keywords

Cyclosporine; Delphi method; Nephrotic syndrome; Tacrolimus

Indexed keywords

ATORVASTATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COUGHING; DELPHI STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DYSLIPIDEMIA; FOCAL GLOMERULOSCLEROSIS; GINGIVA HYPERPLASIA; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOKALEMIA; INFECTION; KIDNEY BIOPSY; MYALGIA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; PEDIATRICS; PRACTICE GUIDELINE; PSYCHOSIS; RASH; SIDE EFFECT; VOMITING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCINEURIN; CHILD; DELPHI TECHNIQUE; EVIDENCE-BASED MEDICINE; HUMANS; NEPHROTIC SYNDROME; RECEPTORS, ANGIOTENSIN; REMISSION INDUCTION;

EID: 58849160788     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Indian Pediatric Nephrology Group, Indian Academy of Pediatrics. Management of steroid sensitive nephrotic syndrome: Revised guidelines. Indian Pediatrics 2008; 45: 203-214.
2. Bagga A, Mantan M. Nephrotic syndrome in children. Indian J Med Res 2005; 122: 13-28.
3. Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecasting 1999; 15: 353-375.
4. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR consensus criteria for classification of childhood vasculitides. Ann Rheum Dis 2006; 65: 936-941.
5. Carruthers SG, Larochelle P, Haynes RB, Petrasovits A, Schiffrin EL. Report of the Canadian Hypertension Society Consensus Conference.1. Introduction. Can Med Assoc J 1993; 149: 289-293.
6. International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 1981; 98: 561-564.
7. Habashi D, Hodson E, Craig J. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database System Rev 2007; 2: CD 003594.
8. Nammalwar BR, Vijayakumar M, Prahlad N. Experience of renal biopsy in children with nephrotic syndrome. Pediatr Nephrol 2006; 21: 286-288.
9. International Study of Kidney Disease in Children. Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int 1981; 20: 765-771.
10. Fujinaga S, Kaneko K, Muto T, Ohtomo H, Murakami H, Yamashiro Y. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child 2006; 91: 666-670.
11. Antignac C. Molecular basis of steroid resistant nephrotic syndrome. Nefrologia 2005; 25 (suppl): 25-28.
12. Hinkes BG, Mucha B, Vlangos CN, Gbadegesin R, Liu J, Hasselbacher K et al: Arbeitsgemeinschaft für Paediatrische Nephrologie Study Group. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007; 119:e907-919.
13. Ruf RG, Lichtenberger A, Karle SM, Has JP, Anacleto FE, Schultheiss M, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15: 722-732.
14. Orloff MS, Iyengar SK, Winkler CA, Goddard KA, Dart RA, Ahuja TS, et al. Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol Genomics 2005; 21: 212-221.
15. Schwaderer P, Knüppel T, Konrad M, Mehls O, Schärer K, Schaefer F, et al. Clinical course and NPHS2 analysis in patients with late steroid-resistant nephrotic syndrome. Pediatr Nephrol 2008; 23: 251-256.
16. Gulati S, Sengupta D, Sharma RK, Sharma A, Gupta RK, Singh U, et al. Steroid resistant nephrotic syndrome. Indian Pediatr 2006; 43: 55-60.
17. Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 2007; 22: 2183-2193.
18. Thomas DB, Franceschini N, Hogan SL, Holder S, Jennette CE, Falk RJ, et al. Clinical and pathological characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006; 69: 920-926.
19. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med 1979; 301: 1301-1306.
20. Garin EH, Orak JK, Hiott KL, Sutherland SE. Cyclosporine therapy for steroid resistant nephrotic syndrome. A controlled study. Am J Dis Child 1988; 142: 985-988.
21. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996; 7: 56-63.
22. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43: 1377-1384.
23. Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994; 4: 1049-1056.
24. Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008; 23: 910-913.
25. Choudhry S, Bagga A, Menon S, Hari P. Randomized controlled trial on efficacy and safety of cyclosporin vs tacrolimus in steroid resistant nephrotic syndrome. Pediatr Nephrol 2007; 22: 1480 (abstract).
26. International Study of Kidney Disease in Children. Prospective, controlled trial of cyclophosphamide therapy in children with the nephrotic syndrome. Lancet 1974; ii: 423-427.
27. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report for the International Study of Kidney Disease in Children. Pediatr Nephrol 1996; 10: 590-593.
28. Elhence R, Gulati S, Kher V, Gupta A, Sharma RK. Intravenous pulse cyclophosphamide - a new regime for steroid resistant minimal change nephrotic syndrome. Pediatr Nephrol 1994; 8: 1-3.
29. Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN. Intravenous cyclophosphamide in steroid resistant nephrotic syndrome. Pediatr Nephrol 2003; 18: 351-356.
30. Adhikari M, Bhimma R, Coovadia HM. Intensive pulse therapies for focal glomerulosclerosis in South African children. Pediatr Nephrol 1997; 11: 423-428.
31. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM. Treatment of steroid resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990; 4: 303-307.
32. Hari P, Bagga A, Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr 2004; 41: 993-1000.
33. Mantan M, Sriram CS, Hari P, Dinda A, Bagga A. Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2008; 23:1495-1502
34. Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W, for Arbeitsgemeinschaft für Pädiatrische Nephrologie. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome - a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol 2008; 23:1483-1493.
35. Rao J, Xu H, Cao Q, Huang WY, Zhou LJ. Comparison of cyclophosphamide and cyclosporine in the treatment of steroid-resistant idiopathic nephrotic syndrome in children. Zhong Nan Da Xue Bao Yi Xue Ban 2007; 32: 958-963.
36. Heng Li, Xiayu Li, Jianghua Chen. Tacrolimus versus pulse intravenous cyclophosphamide therapy in adults with steroid-resistant idiopathic minimal change nephropathy: A prospective case-matched trial in china. J Am Soc Nephrol 2008; 19: 557A
37. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098-1114.
38. Bosch T, Wendler T. Extracorporeal plasma treatment in primary and recurrent focal segmental glomerular sclerosis. Ther Apher 2001; 5: 155-160.
39. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid resistant nephrotic syndrome. N Engl J Med 2007; 356: 2751-2752.
40. Cattran DC, Alexopoulos EH, Heering P, Hoyer PF, Johnston A, Meyrier A, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 2007; 72: 1429-1447.
41. Troyanov S, Wall CA, Mille JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16: 1061-1068.
42. Goumenos DS, Kalliakmani P, Tsakas S, Savidaki I, Vlachojannis JG. Cyclosporin A in the treatment of nephrotic syndrome: the importance of monitoring C0 (trough) and C2 (two hours after administration) blood levels. Med Chem 2006; 2: 391-393.
43. Ahmad H, Tejani A. Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron 2000; 84: 342-346.
44. Yi Z, Li Z, Wu XC, He ON, Dang XO, He XJ. Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2006; 21: 967-972.
45. Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2004; 19: 45-50.
46. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48.
47. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4 (Suppl 7): 13-53.
48. Prescott WA, Streetman DA, Streetman DS. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother 2004; 38: 2105-2114.